Explore the words cloud of the E-T1IFNs project. It provides you a very rough idea of what is the project "E-T1IFNs" about.
The following table provides information about the project.
Coordinator |
THE UNIVERSITY OF EDINBURGH
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Total cost | 2˙418˙800 € |
EC max contribution | 2˙418˙800 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2017-ADG |
Funding Scheme | ERC-ADG |
Starting year | 2018 |
Duration (year-month-day) | from 2018-11-01 to 2023-10-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | THE UNIVERSITY OF EDINBURGH | UK (EDINBURGH) | coordinator | 2˙418˙800.00 |
Type I interferons represent both key molecules in anti-viral defence and mediators of inflammatory disease, so that the induction, transmission and resolution of the interferon response are tightly regulated - balancing protection against infection versus the risk of immunopathology. Monogenic type I interferonopathies (T1IFNs), and related ‘complex’ phenotypes such as systemic lupus erythematosus and dermatomyositis, represent examples of a disturbance of the homeostatic control of this system, where a constitutive upregulation of type I interferon activity is considered directly relevant to pathology.
Set against the absence of a routine assay in clinical medicine for the detection of upregulated type I interferon, the current application addresses major questions in the developing T1IFN field. Analogous to other screening strategies (e.g. using mouse ENU mutagenesis or yeast gene deletion series), we have established a pipeline for the systematic identification of human mutant states predisposing to upregulated type I interferon signalling. Such an approach will allow for the comprehensive definition of important themes in interferon biology, informing our understanding of anti-viral signalling and self-non-self discrimination. Furthermore, these studies will have direct translational benefit - since the identification of a phenotype as a T1IFN implies the possibility of therapy to reduce type I interferon levels and / or block interferon signalling.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "E-T1IFNS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "E-T1IFNS" are provided by the European Opendata Portal: CORDIS opendata.